Posted by Michael Wonder on 18 Sep 2023
Ascendis Pharma receives positive CHMP opinion for TransCon PTH (palopegteriparatide) for adults with chronic hypoparathyroidism
14 September 2023 - Final European Commission decision expected within 67 days after positive opinion; if approved, first European Union launch planned in Germany in early 2024.
Ascendis Pharma today announced that the EMA’s CHMP has adopted a positive opinion and recommended the approval of TransCon PTH (palopegteriparatide) as a parathyroid hormone replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism.
